Michael Cross
Leipzig University
109 Papers
929 Citations
Michael Cross is an academic researcher from Leipzig University. The author has contributed to research in topics: Stem cell & Transplantation. The author has an hindex of 26, co-authored 109 publications. Previous affiliations of Michael Cross include Max Planck Society & University of Mainz.
Chat about Author
Papers
Growth factors in development, transformation, and tumorigenesis
Michael Cross,T. Michael Dexter +1 more
TL;DR: Mammalian tissue development and regeneration take place within a milieu of regulatory growth factors, such that survival, proliferation, differentiation, and certain aspects of cell behavior are all influenced by a balance between stimulatory and inhibitory signals.
729
Mouse lysozyme M gene: isolation, characterization, and expression studies.
TL;DR: Derivation of the amino acid sequence from the nucleotide sequences revealed six positions in the carboxyl terminus that differ from partial sequences previously published, which indicate sites of protein accumulation, rather than gene expression, have been identified by comparative quantitation of mRNA and enzyme levels.
252
Revision of the Human Hematopoietic Tree: Granulocyte Subtypes Derive from Distinct Hematopoietic Lineages
André Görgens,Stefan Radtke,Michael Möllmann,Michael Cross,Jan Dürig,Peter A. Horn,Bernd Giebel +6 more
TL;DR: It is shown that eosinophilic and basophilic granulocytes as well as erythrocytes and megakaryocytes derive from a common ERYthro-myeloid progenitor (EMP), whereas neutrophilicgranulocytes arise independently within a lympho- myeloid branch with long-term progenitors function.
170
Potential of embryonic and adult stem cells in vitro.
Jarosław Czyż,Cornelia Wiese,Alexandra Rolletschek,Przemyslaw Blyszczuk,Michael Cross,Anna M. Wobus +5 more
TL;DR: This review focuses on those issues of embryonic and adult stem cell biology most relevant to their in vitro propagation and differentiation, and questions and problems related to the use of human embryonic andadult stem cells in tissue regeneration and transplantation.
170
Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study
Haifa Kathrin Al-Ali,Nadja Jaekel,Christian Junghanss,Georg Maschmeyer,Rainer Krahl,Michael Cross,Gisa Hoppe,Dietger Niederwieser +7 more
TL;DR: Azacitidine is active and well tolerated in elderly patients with newly diagnosed AML, and lower marrow blasts on day 15 of cycle 1, irrespective of pretreatment count, predicted subsequent response.
119